Tenecteplase is a modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction, pulmonary emboli, and ischemic stroke. Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA).
- Mechanism
- Curator reviewed
Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
- Primary indication
- Tenecteplase is indicated for the treatment of acute ischemic stroke (AIS) in adult patients and to reduce the risk of death in adult patients following acute ST-elevated myocardial infarction (STEMI).Curator reviewed · 4 structured indications
- Formula / weight
- C2561H3919N747O781S40 · 58951.2 Da
- First approval
- Canada, 2001 · United States, 2000 · European Union, 2016
- Also known as
- rhTNK-tPA · TNK · TNK-tPA
- Brand names
Resolves to
What you can answer from here — as of September 12, 2026
Which drugs share a target with Tenecteplase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account